El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

Cancer Reports - 2025 - - Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation.pdf (334.57 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-01-01

Llicència de publicació

cc by (c) Calva, Carolina de la et al, 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/218889

Do unresectable giant cell tumors of bone treated with denosumab progress after discontinuation of treatment?

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1002/cnr2.70117

Resum

BackgroundDenosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who reached the end of treatment.AimsTo analyze the outcomes of patients diagnosed with GCTB and who had finished single treatment with denosumab.Methods and ResultsThis is a multicenter, retrospective, descriptive study carried out in seven Spanish hospitals with multidisciplinary sarcoma and musculoskeletal tumor boards, between 2009 and 2019. Sixteen patients diagnosed with unresectable GCTBs and treated with denosumab who had reached the end of their treatment were recruited for the study and had been followed up for a minimum of 2 years. Fifty percent of patients discontinued denosumab after showing signs of tumor control. The disease remained stable in 69% of patients (n = 11), with a median recurrence-free survival time of 46 months (20-157 months) after being treated for a median period of 19 months (5-83 months). Four patients experienced local progression, and one presented multifocal progression. These five patients were treated for a median period of 46 months (14-76 months), with a median recurrence-free survival time of 9 months (5-25 months).ConclusionThe findings of the present study suggest that discontinuation of denosumab in patients with unresectable GCTB is not necessarily associated with the progression of the disease. Further research is needed to determine how long denosumab should be administered to minimize the risk of recurrence.

Matèries

Tumors de cèl·lules gegants de l'os, Recurrència, Resectable

Matèries (anglès)

Giant cell tumors of bone, Recurrence, Unresectable

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

Deno Research Group, CALVA, Carolina de la, ANGULO SÁNCHEZ, Manuel, GONZÁLEZ ROJO, Paula, PEIRÓ, Ana, MACHADO, Pau, CEBRIÁN, Juan luis, GARCÍA MAROTO, Roberto, VALCÁRCEL, Antonio, PUERTAS GARCÍA-SANDOVAL, Pablo, VALERO CIFUENTES, Gregorio, PABLOS GONZÁLEZ, Óscar, MAIRELES PÉREZ, Míriam, FONTALVA GUERRERO, María luisa, CHAVES, Iván, ORCE, Aida, COLL MESA, Luis, PÉREZ MUÑOZ, Israel, GONZÁLEZ LIZÁN, Fausto, SANZ PASCUAL, María del carmen, GRACIA ALEGRÍA, Isidro. Do unresectable giant cell tumors of bone treated with denosumab progress after discontinuation of treatment?. _Cancer Reports_. 2025. Vol. 8, núm. 1. [consulta: 8 de gener de 2026]. ISSN: 2573-8348. [Disponible a: https://hdl.handle.net/2445/218889]

Exportar metadades

JSON - METS

Compartir registre